English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
Personal Profiles
Professor Peter Valent, MD
Senior Researcher and Senior Clinician
Medical University of Vienna, Austria
Professor Dr. Peter Valent is M.D. and a Senior Researcher as well as Senior Clinician at the Medical University of Vienna, Austria. He is the Scientific Director of the Ludwig Boltzmann Cluster Oncology (LB-CO) and leads a Special Research Program on Myeloproliferative Neoplasms in his University. He also coordinates a Clinical Study Group working in the field of myeloid neoplasms (focusing on CML, MDS, AML and mastocytosis) and is head of the Outpatient Clinics and Hematology Ambulatory in his institution. Professor Valent also participates in several other Research Programs in Vienna, including one dedicated to Cardiovascular Biology (10 years) and one dedicated to Allergic Diseases (20 years). Professor Valent is coordinator of the Vienna Cancer Stem Cell Club (VCSCC), coordinator of an International Working Group on Eosinophil Disorders (ICOG-EO), and coordinator of the European Competence Network on Mastocytosis (ECNM). He also coordinates the CML-Platform and MDS-Platform of the Austrian Society for Hematology and Oncology (ÖGHO), runs a Center of Excellence of the MDS Foundation, a Center of Excellence and Reference Center of the ECNM, and a Reference Center in CML. During the past 15 years, Professor Valent has organized a number of scientific meetings in Vienna, including several Consensus Conferences on Diagnostic Criteria and Diagnostic Standards. A special focus in his research are neoplastic stem cells; the identification of novel markers and targets in myeloid neoplasms; the development of disease-related criteria and targeted drug therapies in myeloid neoplasms; and the evaluation of target interaction profiles and side effects of novel drugs. Professor Valent is member in diverse Medical Societies, including the American Society of Hematology (ASH), and serves on various editorial boards and as a reviewer in most top hematology journals. He published more than 500 peer-reviewed articles and numerous review articles in his areas of expertise, lectured widely in Europe, North America, and
Professor Francois-Xavier Mahon
Professor and Senior House Physician
University of Bordeaux, France
Professor Mahon gratuated in clinical hematology from the faculty of medicine, University of Bordeaux and received a PhD for his work on "Selection of Normal Cells in Chronic Myeloid Leukaemia". Professor Mahon has completed a Research Fellowship at the Imperial College in London (UK) and is a felllow of the American Society of Hematology (ASH), the European Hematology Association (EHA), the French Society of Hematology, and the European Investigators on CML Group (El-CML). He currently serves as the President of the French Group of CML (Fl-LMC) and today has authored or co-authored for than 160 articles in peer-reviewed journals.
Professor of Medicine Chair, Department of Haematology Hammersmith Hospital
Imperial College, London (UK)
Professor Jane Apperley is the Chair of the Department of Haematology at the Imperial College and the Chief of Service for Clinical Haematology at the Imperial College Healthcare NHS Trust in London, England. Jane Apperley served as the President of both the European Group of Blood and Marrow Transplantation and the British Society of Blood and Marrow Transplantation. She also serves on the Advisory Board of the Centre for International Blood and Marrow Transplant Research.
She qualified in Medicine from the University of Birmingham and after initial specialization in internal medicine she completed specialist training in hematology in Birmingham, London, Cambridge and Boston.
Her particular interests are the biology and management of CML, which has led to an extensive experience in stem cell transplantation and to the use of signal transduction inhibitors. Her group at the Hammersmith Hospital site has extensive experience in the use of the first- and second-generation TKI’s, particularly in the areas of molecular monitoring and mechanisms of drug resistance. She has a long-standing interest in the ways in which hematologic diseases and their treatment impact fertility, pregnancy, and fetal outcome.
Leader, Myeloproliferative Neoplasms (MPN) Program
Memorial Sloan-Kettering Cancer Center, New York
Professor Michael Mauro directs the Myeloproliferative Neoplasms (MPN) Program at the Memorial Sloan-Kettering Cancer Center in New York. He received his medical degree from Dartmouth Medical School and completed his residency and fellowship training at New York-Presbyterian Hospital/Weill Cornell Medical Center. For more than a decade he worked with Dr Brian Druker at the OHSU Knight Cancer Institute in Portland, Oregon with a focus on research in CML. There he directed the CML clinical trial program and was involved in the early development and sentinel clinical study of targeted therapy for CML. His clinical focus is in CML with interest in therapy optimization, novel therapies, treatment free remission and pregnancy/fertility, as well as other myeloproliferative neoplasms, including myelofibrosis, polycythemia and thrombocytosis and less common conditions such as eosinophillic and mast cell disorders.
Jeff Lipton, PhD MD FRCPC
Jeff Lipton is Professor of Medicine at the University of Toronto and Staff Physician on the Leukemia and Allogeneic Blood and Marrow Transplant Services at the Princess Margaret Hospital. He received and honors BSc in Biochemistry at the University of Calgary and went on to a PhD in Biochemistry at the University of Western Ontario. An MRC post-doctoral fellowship at the Weizmann Institute in Israel with Leo Sachs led to his developing interests in leukemia. After a short time as a junior staff at the University of Connecticut, he had a mid-life crisis and went back to Calgary to go to medical school, followed by a residency in Internal Medicine. He then completed sub-specialty training in Medical Oncology at the University of Toronto and stayed on at the PMH as a staff physician. His clinical practice is in chronic leukemias and bone marrow failure syndromes as well as allogeneic stem cell transplant. Research interests in particular are in CML and its therapy, outcomes and supportive care in BMT, and in the therapy of bone marrow failure syndromes. Jeff serves on the Unrelated Donor Transplant Advisory Board of OneMatch, Past President of the Canadian Bone Marrow Transplant Group (CBMTG), was an advisor to the Center for Research on Bone Marrow Transplantation (CIBMTR), has served on the Clinical Trials Group of the CBMTG, was Director of the Allogeneic Stem Cell Transplant Program at PMH, is Head of the CML Study Group at PMH and is on several international advisory boards relating to the therapy of CML including the International CML Foundations and the ELN and Canadian CML Guidelines Committee. He has authored or co-authored more than 250 peer reviewed papers and 350 abstracts.
Nick Cross, MA PhD FRCPath
Nick Cross MA PhD FRCPath studies at the University of Cambridge, initially reading Natural
Sciences and subsequently undertaking a PhD in the Department of Genetics. He started his postdoctoral career at the Hammersmith Hospital, London in 1987, where he developed an interest in chronic myeloid leukaemia under the mentorship of Prof John Goldman. In 2001 he relocated to Salisbury to take up Directorship of the Wessex Regional Genetics Laboratory and Chair of Human Genetics at the University of Southampton. His research, which has resulted in more than 290 peer reviewed publications, focuses on the molecular pathogenesis of myeloid malignancies as well as the development, validation and standardisation of genetic tests.
Charles A. Schiffer, MD, is Professor of Medicine and Oncology at Wayne State University School of Medicine and the Karmanos Cancer Institute in Detroit, Michigan. He is the director of the Leukemia/Lymphoma Multidisciplinary Program.
Dr. Schiffer earned his BA cum laude at Brandeis University and his M.D. at New York University School of Medicine. He completed his internship, residency, and chief residency in Internal Medicine at Bellevue Hospital under the auspices of New York University School of Medicine and had subsequent training and positions at the Baltimore Cancer Research Institute, National Cancer Institute and the University of Maryland School of Medicine, where he served as Chief of the Division of Hematology. He has also served as Chief of the Division of Hematology/Oncology and Director of Clinical Research at the Karmanos Cancer Institute.
Dr. Schiffer has authored and co-authored more than 300 articles and 80 book chapters on topics concerning the treatment of leukemia in adults, platelet transfusion, and granulocyte transfusion therapy, among others. He has served on the Editorial Boards for Blood, the Journal of Clinical Oncology, International Journal of Hematology, Transfusion Medicine Reviews and Transfusion, and reviews articles for multiple journals. Committee memberships have included Chairman of the Leukemia Committee of the Cancer and Leukemia Group B, Chairman of the Food and Drug Administration Oncologic Drug Advisory Committee, and grant reviews for the NCI and Leukemia/Lymphoma Society of America. Dr. Schiffer has been named among American Health Magazine’s and Castle Connelly’s “Best Doctors in America,” “Best Cancer Specialists in the US.” In 2006, he received the Dr. John J. Kenney Award from the Leukemia/Lymphoma Society of America and the Celgene Award for Career Achievement in Hematology. He has received multiple teaching awards from Wayne State University and was recently inducted into the Academy of Scholars, the highest recognition accorded to academic faculty at the University.
